Flupentixol
Flupentixol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against D(2) dopamine receptor and D(1A) dopamine receptor. In addition, it is known to target D(3) dopamine receptor and D(1B) dopamine receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | 2 | 3 | 7 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 1 | 1 | 3 | 5 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | 1 | 3 | 4 |
| Depression | D003863 | — | F33.9 | — | — | 1 | 1 | — | 2 |
| Tinnitus | D014012 | — | H93.1 | — | — | — | 1 | — | 1 |
| Compliance | D003187 | — | — | — | — | — | 1 | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | 1 | — | 1 |
| Therapeutics | D013812 | — | — | — | — | — | 1 | — | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | — | — | — | 1 | — | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | 1 | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Globus sensation | D000079564 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | 3 | — | — | — | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | — | — | 2 |
| Microvascular angina | D017566 | — | — | 1 | 1 | — | — | — | 1 |
| Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 2 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Weight loss | D015431 | — | — | — | — | — | — | 1 | 1 |
| Mania | D000087122 | — | F30 | — | — | — | — | 1 | 1 |
| Breast feeding | D001942 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Flupentixol |
| INN | flupentixol |
| Description | Cis-flupenthixol is a flupenthixol in which the double bond adopts a cis-configuration. It has a role as a dopaminergic antagonist. It is a conjugate base of a cis-flupenthixol(2+). |
| Classification | Small molecule |
| Drug class | Typical antipsychotic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 53772-82-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL54661 |
| ChEBI ID | 10454 |
| PubChem CID | 5281881 |
| DrugBank | DB00875 |
| UNII ID | 21HMQ851IS (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,283 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,680 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use